Today’s cyclodextrin
I just signed the contract sealing a long-term collaboration between Semmelweis University – a leading medical education institution in Hungary and the Central European region – and CarboHyde.
We will work closely in the coming 2 years with Ákos Lőrincz and Mátka Nagy ,exploring how cyclodextrins could be combined with extracellular vesicles for practical applications.
Ending the Bicyclos HEurope secondments, our staff is full again (until January).
To celebrate this, we gathered with our wider team including Fahad Khan Tareen, Eszter Kalydi, Mátka Nagy, József Tóth and Szejtli Gabriella.
Such a memorable night.
Our webinar, titled “Cyclodextrins in small molecule drug delivery – current trends and future directions” is the first episode in a series of webinars (CarboHyde’s Cyclodextrin Masterclass) that aims to provide educative content to cyclodextrin users and researcher on various applications.
Event Overview: Join us for an illuminating webinar that traces the evolution of cyclodextrin-based drug delivery systems—from current mainstream applications towards future trends. Our esteemed speaker will explore key aspects of this journey, highlighting breakthroughs, challenges, and the promise of cyclodextrins in improving therapeutic outcomes.
How inspiring it is to discuss common interests around gene delivery with a Nobel Laurate?
Well, now Kristóf Felegyi and Balázs Attila Kondoros have first-hand experience about that after meeting Katalin Karikó at the mRNA conference in Szeged.
What a lifetime memory!
No doubt our projects at GENEGUT will benefit a lot from this event too.
More information about the scientific program: mRNA Conference, Szeged
We are happy to share this little beta version game that Balázs Attila Kondoros and Kristóf Felegyi put together during their Bicyclos HEurope secondment. Special thanks for the support and guidance of Angel Piñeiro and Rebeca Garcia-Fandino for their amazing work.
Molvelle AR Software was developed within the framework of the European Bicyclos project (EC-funded Staff Exchange project n° 101130235) in collaboration with the University of Santiago de Compostela, MD.USE Innovative Solutions S.L., Carbohyde, and IES Rosalía de Castro, Santiago de Compostela.
Enjoy!
Our webinar, titled “Cyclodextrin formulations: The Journey from the Benchtop to the Patients“, brings together experts who will guide us through the milestones of this remarkable journey.
Event Overview: Join us for an illuminating webinar that traces the evolution of cyclodextrin-based drug delivery systems—from laboratory research to real-world patient care. Our esteemed speakers will explore key aspects of this journey, highlighting breakthroughs, challenges, and the promise of cyclodextrins in improving therapeutic outcomes.
Agenda:
Great article in this month’s issue of Drug Development & Delivery featuring cyclodextrins and other solubilization techniques.
Ardena‘s Drug Product team, led by Vincent Levet (Director, Formulation Development and Production) and Timothy Pas (Group Leader, Formulation Development and Production), has just published this technical article that explores innovative formulation strategies aimed at addressing solubility and bioavailability challenges in poorly soluble drugs. The article focuses on advanced techniques like Amorphous Solid Dispersions (ASDs), lipid-based formulations, Nanosuspensions, and hashtag#Cyclodextrin complexes.
The team highlights how these approaches can accelerate time-to-market while ensuring optimal therapeutic outcomes.
Great contributions from Ferenc Fenyvesi, Ildikó Bácskay (University of Debrecen) and Milo Malanga PhD (CarboHyde)
This has been one of the most fluorishing relationships of our company with many interesting and groundbreaking common projects we will share in the future.
The most anticipated pharmaceutical event of the year is fast approaching! CPHI 2024, set to take place in Milan from October 8-10, is the world’s largest pharmaceutical exhibition. This event is a unique convergence of six individual pharma sectors, covering every aspect of the industry—from ingredients and FDF to machinery, packaging, outsourcing, and biopharmaceuticals.
This year’s CPHI is shaping up to be bigger and better than ever. Here’s what attendees can look forward to:
For those who have previously attended a CPHI event, you’ll know that it’s tailored specifically for professionals in the pharmaceutical industry. Whether you’re looking to network, learn, or explore new business opportunities, CPHI is the place to be.
Among the myriad of products and technologies on display, cyclodextrins will feature prominently at CPHI 2024. Expect to meet a wide range of users and manufacturers of cyclodextrins, including:
And, of course, CarboHyde will be there too. Our team will be well-represented, with CFO Gergely Toth, COO Tamás Vargadi, and Tamas Sohajda all attending the event. We’re excited about the opportunity to engage with industry peers and discuss potential collaboration on cyclodextrin projects.
If you’re planning to attend CPHI in Milan, we would love to catch up with you. This event presents a fantastic opportunity to plan and strategize around cyclodextrin-related projects. We believe that face-to-face interactions at such a prestigious event can pave the way for meaningful collaborations.
We look forward to seeing you there!
Johannesburg, South Africa, and Budapest, Hungary – [28/08/2024] – The University of the Witwatersrand (WITS), a leading research institution in South Africa, and CarboHyde Zrt, a pharmaceutical company based in Hungary, have entered into a strategic collaboration to advance the development of a novel breast cancer therapeutic. This partnership aims to accelerate the development of this asset further while securing funding opportunities within Europe and ensuring the successful progress of this promising therapeutic from research to market.
The collaboration between WITS and CarboHyde will be executed in multiple phases: first, finishing the preclinical studies, and later, starting clinical trials together or with other partners.
This collaboration marks a significant milestone in the fight against breast cancer, combining the strengths of two innovative organizations across continents. By pooling their resources, expertise, and networks, WITS and CarboHyde aim to bring this cutting-edge therapeutic to market, benefiting patients and healthcare systems worldwide.
For more information, please contact CarboHyde at info@carbohyde.com
About the University of the Witwatersrand: The University of the Witwatersrand (WITS) is a leading research-intensive institution based in Johannesburg, South Africa. WITS is dedicated to advancing knowledge through impactful research and is recognized globally for its contributions to science and innovation.
About CarboHyde Zrt: CarboHyde is a pharmaceutical company based in Budapest, Hungary, specializing in carbohydrate chemistry, including cyclodextrins. CarboHyde focuses on creating innovative solutions and collaborating with partners worldwide to bring breakthrough technologies to market in the pharmaceutical arena.